Oesophageal Cancer Trial, Recruiting NCT04117100 Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT04117100
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

  • People who are older than 18 years of age.
  • People who are scheduled for a planned, non-emergency advanced endoscopy procedure (such as removal of abnormal tissue or polyps, or treatment of certain conditions in the throat or oesophagus).
  • People who have read, understood, and signed a consent form agreeing to participate.

Who may not be able to join:

  • People who are unable to understand what the trial involves, or who are unwilling to give their consent to participate.
  • People who have a blood clotting disorder that affects how their blood clots.
  • People whose general health is considered poor, based on a standard medical rating scale used by anaesthetists (confirm with trial site for details on how this is assessed).
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel von Renteln, MD,PhD, Centre Hospitalier Universitaire de Montréal (CHUM)

Phone: 514-890-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Registry
ClinicalTrials.gov
Start date
1 June 2018
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Assess the incidence of overall severe complications following the procedure; Assess the rate of completeness of neoplastic tissue resection; Severe bleeding complications; Assess the presence of perforation at resection site; Assess the number of patients with post-polypectomy syndrome; Assess the efficacy of submucosal injectate; Assess the number of patients with intraprocedural bleeding; Assess the number of patients with the need for surgical resection; Technical skill of the endoscopist; En-bloc resection rate; R0 resection rate; Local recurrence rate; Distant metastasis rate; Lymph node...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov